Tag: bioequivalence

post-image
May, 18 2026

Global Perspectives on Generics: How International Policies Shape Drug Prices and Access

Explore how international policies shape the generic drug market, from US savings to China's price cuts. Understand the balance between affordability, quality, and innovation.
post-image
Apr, 20 2026

Brand vs Generic Medications: Do Inactive Ingredients Cause Side Effects?

Explore why some people react differently to brand vs generic meds. Learn how inactive excipients can cause side effects and which drugs require caution.
post-image
Apr, 13 2026

Authorized Generics vs Brand Name Drugs: Are They Truly Equivalent?

Discover if authorized generics are truly equivalent to brand-name drugs. Learn the FDA rules, clinical differences, and how to save on your medication safely.
post-image
Dec, 19 2025

FDA Authorization of Generics: Legal Basis and Approval Process

Learn how the FDA legally authorizes generic drugs through the Hatch-Waxman Act and ANDA pathway, ensuring they're as safe and effective as brand-name drugs while cutting costs by up to 85%.
post-image
Dec, 9 2025

How to Compare Bioavailability and Bioequivalence in Generic vs Brand Drugs

Learn how bioavailability and bioequivalence ensure generic drugs work just like brand-name versions. Understand the science behind generic approval, real-world outcomes, and why these standards keep patients safe.
post-image
Nov, 16 2025

Generic vs Brand-Name Drugs: Key Differences Explained

Generic drugs save up to 85% on costs and are just as safe and effective as brand-name versions. Learn how the FDA ensures they work the same, why they look different, and when you might still need the brand.
post-image
Nov, 14 2025

The 80-125% Rule: Understanding Bioequivalence Confidence Intervals

The 80-125% rule ensures generic drugs perform like brand-name versions by measuring how much of the drug enters your bloodstream. It's not about pill strength-it's about absorption. Learn how regulators use confidence intervals to guarantee safety.